Fuji astaxanthin earns GRAS go-ahead
This article was originally published in The Tan Sheet
Executive SummaryFuji Chemical Industry Co. can use AstaREAL astaxanthin in food and beverage applications, following FDA's letter of no objection to the ingredient's generally recognized as safe status. Fuji said Jan. 12 the agency's tacit approval increases U.S. marketing opportunities and global awareness of astaxanthin, a carotenoid antioxidant found in seafood. Charles DePrince, president of the Japanese pharmaceutical company's U.S. subsidiary in Burlington, N.J., said in a release that the firm is committed to quality and safety, and the GRAS notification Fuji submitted in July 2009 includes purity specifications unique to AstaREAL
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.